Serum thyroxin-binding globulin (TBG) concentrations measured by immunoradiometric assay (Corning kit) in patients with nonthyroidal illnesses (NTI) had previously been found to be lower than those measured by radloimmunoassay. Because some of these patients were receiving newly recognized inhibitors of thyroid hormone binding-furosemide, diclofenac, fenclofenac, or met enamic acid-we tested whether the binding of labeled thyroxin to TBG (the principle of the kit) was inhibited by these drugs. We also tested lipids, including free fatty acids (FFA), because most patients with NTI exhibit a thyroid-hormone-binding inhibiting activity in the circulation that apparently is related to unsaturated FFA. We found that, among lipids, unsaturated FFA inhibit thyroidhormone binding, according to the degree of unsaturation. For nonlipid drugs the order of potency of inhibition is furosemide > diclofenac = mefenamic acid > phenytoin > heparin. We conclude that the TBG Corning kit is a convenient and rapid method for testing the inhibition of thyroid hormone binding, but that an RIA should be used to measure circulating TBG in NTI patients, especially in those receiving furosemide. proportion of the sera with low concentrations of TBG were from patients with severe NTI, e.g., cancer and chronic renal failure, some of whom were taking analgesics such as diclofenac, or the diuretic, furosemide. At the time of these studies, the inhibitory activity exerted by furosemide, diclofenac, mefenamic acid, and unsaturated FFA on the interaction between thyroid hormones and serum proteins had not yet been reported. Since then, we decided to test whether the presence in plasma of the newly recognized lipid or nonlipid inhibitors could interfere with the immunoradiometric assay through inhibiting the binding of labeled T4, and thus leading to measurement of a spuriously low concentration of circulating TBG. We also wanted to determine whether the Corning kit could be used as a rapid test for inhibitory compounds. Here we report our findings.
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Numerous drugs affect the binding of the thyroid hor-
mones, thyroxin (T4)4 and triiodothyronine (T3), to the major thyroid hormone transport proteins, thyroxin-binding globulin (TBG), prealbumin (also known as transthyretin), and albumin. Apart from the most well known, such as phenythin and the salicylates (1), other drugs have recently been recognized as inhibiting the interaction between thyroid hormones and their protein transport system in plasma. These latter include the non-steroidal anti-inflammatory agents, mefenamic acid (2), fenclofenac, and diclofenac (3,4), and the diuretic, furosemide (5, 6). Moreover, nonesterified or free fatty acids (FFA) are also competitive inhibitors of the binding of thyroid hormones to serum proteins (for references see 7). The practical effect of this inhibitory activity is to alter results of thyroid-function tests, leading
to low values for serum T4 and T3, with the potential misdiag'nosis of hypothyroidism. In addition, measurement of free thyroid hormones is also affected by FFA (7) .
Measurement of TBG in serum is currently of interest as a prognostic index for impending death or clinical recovery
in patients with serious nonthyroidal illnesses (NTI) (8, 9) . Although the concentration of prealbumin is a more sensi- with anti-human TBG antibody covalentlybound to glass particles. The major advantages of this method are its practicality and its short incubation time (as little as 10 mm at room temperature).
In the laboratory of the Istituto Plurodisciplinaire di
Clinics Medics, two of us found the performance of this kit to be satisfactory and unaffected by low concentrations of circulating T4 autoantibodies having a moderate affinity for T4 (14, 15) . We found (unpublished data) an excellent correlation (r = 0.89, P <0.001, n = 40) between TBG as measured by the Corning kit and by a radioiminunoassay proportion of the sera with low concentrations of TBG were from patients with severe NTI, e.g., cancer and chronic renal failure, some of whom were taking analgesics such as diclofenac, or the diuretic, furosemide. At the time of these studies, the inhibitory activity exerted by furosemide, diclofenac, mefenamic acid, and unsaturated FFA on the interaction between thyroid hormones and serum proteins had not yet been reported. Since then, we decided to test whether the presence in plasma of the newly recognized lipid or nonlipid inhibitors could interfere with the immunoradiometric assay through inhibiting the binding of labeled T4, and thus leading to measurement of a spuriously low concentration of circulating TBG. We also wanted to determine whether the Corning kit could be used as a rapid test for inhibitory compounds. Here we report our findings.
Materials and Methods
All the chemicals and drugs were from Sigma Chemical Co., St. Louis, MO, and certified to be about 99% pure. We checked the purity of the lipids by thin-layer chromatography on silica gel plates (Whatman, Clifton, NJ) using a freshly prepared mixture The samples were taped and covered with aluminum foil, because most lipids are sensitive to light and air, and allowed to equilibrate at 23 #{176}C for 40 mm. We then centrifuged the samples at 3000 x g for 20 mm at 4#{176}C and counted the radioactivity in the precipitate, in a garomacounter.
Standards (used as B0 in the expression of the results) were prepared in sextuplicate for both types of inhibitors; the other samples were assayed in duplicate. Experiments repeated on another day confirmed the results reported below.For oleic acid only, we also used TBG standards of 40 and 30 mg/L.
Results and Discussion
The results obtained for the lipids are summarized in Figure 1 and those for the non-lipid inhibitors in Figure 2 . Both kinds of compounds exert dose-dependent inhibition on the binding of T4 by TBG, but the amount of inhibition varies from one substance to another.
Among the lipids, only unsaturated FFA were effective. The order of inhibitory potency (molar basis) is arachidonic acid > linoleic acid > oleic acid, which is related to the number of double bonds (four, two, and one, respectively). The greater effectiveness of arachidonic acid over oleic acid has been noted previously by Chopra et al. (12, 13) . ArachiAccording to the current standardized terminology of the International Union of Pure and Applied Chemistry (IUPAC) and the International Union on Biochemistry (IUB), the monoglycerides, diglycerides, and triglycerides are to be designated monoacylglycerols, diacyiglycerols, and ti-iacylglycerols, respectively. As shown in Figure 2 , the most potent nonlipid inhibitor is furosemide (50% displacement at 5 imolIL). Diclofenac and mefenamic acid at 50 mol/L and phenytoin at 100 molfL gave 50% displacement. Heparin had little effect. The order of the inhibitory effect is therefore furosemide> diclofenac = mefenamic acid > phenytoin> heparin, which is the order found by Stockigt et al. (6),6 who used dextrancharcoal and more classical equilibrium dialysis techniques for separating bound hormone from free. Therapeutic concentrations for furosemide, mefenamic acid, phenytoin, and heparin are 3, 80, 40, and 1.7 prnol/L, respectively (6), although furosemide may be used at doses so high that its concentration in serum can be as much as 10-fold greater than this. Therapeutic concentrations of diclofenac are about 3 mg/L (3), or 9.4 mol/L. From these data we can calculate the in vivo drug/TBG molar ratio in plasma of normal or of NTI subjects, assuming TBG concen- serum by immunoradiometric assay. The in vivo mean molar ratio of serum FFA to serum TBG is 54 for arachidonic acid, 190 for stearic acid, 510 for palmitic acid, and 570 for linoleic and oleic acid in healthy individuals. The ratios change to 27, 810, 2600, 3900, and 7000, respectively, in NTI subjects with detectable THBI in serum. We calculated these ratios from Table I bind fatty acids (16, 17) . The plasma might also contain THBI substances other than FFA, but our study did not elucidate these points.
In summary, our findings caution against the use of the immunoradiometric assay as a method to determinecirculating TBG in critically ill patients, especially those receiving furosemide or other drugs capable of binding to TBG.
The TBG concentration determined by such a method may be falsely low and, therefore, misleading when the TBG concentration is used as a biochemical index to follow the clinical condition of NTI patients. In these types of patients, radioimmunoassay is the method of choice to measure circulating TBG. However, the immunoradiometric assay of TBG may be used as a convenient, rapid, and reproducible procedure to test whether a particular substance inhibits the interaction between T4 and TBG.
